[go: up one dir, main page]

AR025386A1 - Moduladores de los receptores activados del proliferador de peroxisomas - Google Patents

Moduladores de los receptores activados del proliferador de peroxisomas

Info

Publication number
AR025386A1
AR025386A1 ARP000104410A ARP000104410A AR025386A1 AR 025386 A1 AR025386 A1 AR 025386A1 AR P000104410 A ARP000104410 A AR P000104410A AR P000104410 A ARP000104410 A AR P000104410A AR 025386 A1 AR025386 A1 AR 025386A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
independently
cycloalkyl
substituted
Prior art date
Application number
ARP000104410A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Ligand Pharm Inc filed Critical Lilly Co Eli
Publication of AR025386A1 publication Critical patent/AR025386A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se dirige a compuestos representados por la Formula estructural (1) y sus sales, solvatos e hidratos farmacéuticamente aceptables y a métodosde preparacion, métodos de utilizacion y composiciones farmacéuticas que tienen compuestosrepres entados por la Formula estructural (1) y sus sales, solvatos ehidratos farmacéuticamente aceptables. En la Formula estructural (1), n es 2, 3 o 4; V es O o S; W es O, S o SO2; R1 es H, alquilo C1-4, fenilo otrifluorometilo; R2 son cada uno,independi entemente, H, alquilo C1-6, aril-alquilo C1-6, cicloalquil-alquilo C1-4, arilo, cicloalquilo o, junto con el feniloal que están unidos, forman naftilo o 1,2,3,4-tetrahidronaftilo; R3 son cada uno, independientemente, H, alquilo C1-6,aril-alquilo C1- 6, cicloalquil-alquiloC1-4, arilo o cicloalquilo; R4 son cada uno, independientemente, H, alquilo C1-4, arilo o benzoílo; R5 son cada uno, independientemente, H, arilo substituido ono substituido o un heteroarilo, siempre que almenos un R5 sea un ar ilo substituido o no substituido o un heteroarilo substituido o no substituido; y R6 es H,alquilo C1-4 o aminoalquilo.
ARP000104410A 1999-08-27 2000-08-25 Moduladores de los receptores activados del proliferador de peroxisomas AR025386A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15116299P 1999-08-27 1999-08-27

Publications (1)

Publication Number Publication Date
AR025386A1 true AR025386A1 (es) 2002-11-27

Family

ID=22537578

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104410A AR025386A1 (es) 1999-08-27 2000-08-25 Moduladores de los receptores activados del proliferador de peroxisomas

Country Status (13)

Country Link
US (3) US6417212B1 (es)
EP (1) EP1206457B1 (es)
JP (1) JP2003508389A (es)
AR (1) AR025386A1 (es)
AT (1) ATE252091T1 (es)
AU (1) AU7073400A (es)
CA (1) CA2382966A1 (es)
DE (1) DE60005973T2 (es)
DK (1) DK1206457T3 (es)
ES (1) ES2204684T3 (es)
PE (1) PE20010529A1 (es)
PT (1) PT1206457E (es)
WO (1) WO2001016120A1 (es)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
AU8588798A (en) * 1997-07-25 1999-02-16 Institut Pasteur Human peroxisome proliferator activated receptor gamma (ppargamma) gene re gulatory sequences and uses therefor
WO2002009691A1 (en) * 2000-08-02 2002-02-07 Pharmanutrients Methods and compositions for the prevention and treatment of syndrome x
EP1310494B1 (en) * 2000-08-11 2012-01-25 Nippon Chemiphar Co., Ltd. PPAR (delta) ACTIVATORS
WO2002016332A1 (en) * 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
AU2001284658A1 (en) 2000-08-23 2002-03-13 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
BR0113409A (pt) 2000-08-23 2003-07-01 Lilly Co Eli Agonistas de receptores ativados por proliferadores de peroxissomas
GB0029974D0 (en) * 2000-12-08 2001-01-24 Glaxo Group Ltd Chemical compounds
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
GB0113231D0 (en) 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
NZ529351A (en) * 2001-06-07 2006-01-27 Lilly Co Eli Modulators of peroxisome proliferator activated receptors
MXPA03010903A (es) * 2001-06-07 2004-02-17 Lilly Co Eli Moduladores de receptores activados por el proliferador de peroxisomas.
AR036237A1 (es) * 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
US20110065129A1 (en) 2001-07-27 2011-03-17 Lowe Derek B Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
BRPI0211844B8 (pt) * 2001-08-10 2021-05-25 Nippon Chemiphar Co composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica
MXPA04002330A (es) 2001-09-14 2005-04-08 Japan Tobacco Inc Compuestos biarilo ligados.
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds
EA007163B1 (ru) 2001-11-30 2006-08-25 Эли Лилли Энд Компани Агонисты рецепторов, активируемых пероксисомным пролифератором
AU2003214932A1 (en) 2002-02-25 2003-09-09 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
JPWO2003091211A1 (ja) * 2002-03-28 2005-09-02 住友製薬株式会社 新規ヘテロアリール化合物
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
UA79755C2 (en) * 2002-04-16 2007-07-25 Bayer Pharmaceuticals Corp Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
BR0311834A (pt) 2002-06-19 2005-04-12 Lilly Co Eli Composto, composição farmacêutica, métodos para mudular um receptor ativado por proliferador de peroxisoma, para tratar e prevenir diabetes mellitus em um mamìfero e para tratar sìndrome x em um mamìfero, e, uso de um composto ou seu sal farmaceuticamente aceitável
US7192970B2 (en) * 2002-11-26 2007-03-20 Chipscreen Biosciences, Ltd. Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity
WO2004063166A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heterocyclic ppar modulators
US7319170B2 (en) * 2003-01-17 2008-01-15 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzensulfonmide derivatives
ES2297382T3 (es) 2003-02-14 2008-05-01 Eli Lilly And Company Derivados de sulfonamida como moduladores de ppar.
US20070105959A1 (en) * 2003-03-11 2007-05-10 Shinya Kusuda Cynnamyl alcohol derivative compounds and drugs containing the compounds as active ingredient
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301009D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
KR20060121884A (ko) * 2003-09-22 2006-11-29 오노 야꾸힝 고교 가부시키가이샤 페닐초산 유도체, 그 제조 방법 및 용도
UA84035C2 (ru) 2003-10-31 2008-09-10 Янссен Фармацевтика Н.В. Производные феноксиуксусных кислот, полезные как двойные агонисты активированных рецепторов пероксисомального пролифератора (ppar)
US20070208021A1 (en) * 2004-03-30 2007-09-06 Daiichi Pharmaceutical Co., Ltd. Phenoxyacetic Acid Derivatives and Drug Comprising The Same
JP4733692B2 (ja) * 2004-04-28 2011-07-27 エフ．ホフマン−ラ ロシュ アーゲー Ｐｐａｒ活性化剤としてのピラゾールフェニル誘導体
CN100344618C (zh) * 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物
WO2005115383A2 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of ppar and methods of their preparation
WO2005115384A2 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
GB0415320D0 (en) * 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
DE602005010444D1 (de) 2004-08-17 2008-11-27 Galderma Res & Dev Neuartige biaromatische ppar-rezeptoren aktivierende zusammensetzungen und ihre verwendung in kosmetischen oder pharmazeutischen zusammensetzungen
FR2874379B1 (fr) * 2004-08-17 2006-10-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
ATE413167T1 (de) * 2004-08-17 2008-11-15 Galderma Res & Dev Neuartige biaromatische ppar-rezeptoren aktivierende zusammensetzungen und ihre verwendung in kosmetischen oder pharmazeutischen zusammensetzungen
FR2874378B1 (fr) * 2004-08-17 2006-10-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
PT1817282E (pt) 2004-11-23 2011-09-19 Astrazeneca Ab Derivados do ácido fenoxiacético úteis para tratar doenças respiratórias
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
EP1937632A1 (en) 2005-10-06 2008-07-02 Astra Zeneca AB Novel compounds
US20080255150A1 (en) * 2005-11-05 2008-10-16 Astrazeneca Ab Novel Compounds
ES2380683T3 (es) * 2005-12-15 2012-05-17 Astrazeneca Ab Difenil-éteres, -amidas, -sulfuros y - metanos sustituidos para el tratamiento de la enfermedad respiratoria
US8023825B2 (en) * 2006-04-04 2011-09-20 Cisco Technology, Inc. Optical switching architectures for nodes in WDM mesh and ring networks
CN101466687B (zh) 2006-04-18 2012-04-11 日本化学医药株式会社 过氧化物酶体增殖剂激活受体δ的激活剂
CN101443330B (zh) * 2006-06-13 2012-12-19 上海海和药物研究开发有限公司 杂环非核苷类化合物及其制备方法、药物组合物和作为抗病毒抑制剂的用途
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
MX2010011252A (es) 2008-04-15 2010-11-30 Nippon Chemiphar Co Activador para el receptor activado por el proliferador de peroxisoma.
AU2009307656B2 (en) * 2008-10-21 2015-07-02 Cymabay Therapeutics, Inc. Aryl GPR120 receptor agonists and uses thereof
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
KR20220151045A (ko) 2014-12-23 2022-11-11 4디 파마 리서치 리미티드 면역 조정
CA2970234A1 (en) 2014-12-23 2016-06-30 4D Pharma Research Limited Pirin polypeptide and immune modulation
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
TW202222339A (zh) 2015-06-15 2022-06-16 英商4D製藥研究有限公司 包含細菌菌株之組合物
MD3360559T2 (ro) 2015-06-15 2020-02-29 4D Pharma Res Ltd Compoziții conținând tulpini bacteriene
ES2753779T3 (es) 2015-06-15 2020-04-14 4D Pharma Res Ltd Blautia stercosis y wexlerae para la utilización en el tratamiento de enfermedades inflamatorias y autoinmunes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
US9839655B2 (en) 2015-11-20 2017-12-12 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
CA3016179C (en) 2016-03-04 2019-08-13 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
SI3630136T1 (sl) 2017-05-22 2021-08-31 4D Pharma Research Limited Sestave, ki zajemajo bakterijske seve
JP6978514B2 (ja) 2017-05-24 2021-12-08 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited 細菌株を含む組成物
LT3638271T (lt) 2017-06-14 2021-01-11 4D Pharma Research Limited Kompozicijos, apimančios bakterines padermes
WO2018229236A2 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
EP3858367A1 (en) 2017-06-14 2021-08-04 4D Pharma Research Limited Compositions comprising bacterial strains
US11498903B2 (en) 2017-08-17 2022-11-15 Bristol-Myers Squibb Company 2-(1,1′-biphenyl)-1H-benzodimidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
JPH07505647A (ja) * 1992-04-10 1995-06-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 複素環化合物および２型糖尿病の治療におけるそれらの使用
RU2134686C1 (ru) 1992-07-03 1999-08-20 Смитклайн Бичам П.Л.С. Гетероциклическое соединение, или его таутомерная форма, и/или фармацевтически приемлемая соль, и/или фармацевтически приемлемый сольват, фармацевтическая композиция, снижающая содержание глюкозы в крови, способ лечения и/или профилактики гипергликемии
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
CA2215387A1 (en) 1995-03-20 1996-09-26 Michael R. Briggs Modulators of ob gene and screening methods therefor
US6022897A (en) * 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
JPH08325250A (ja) 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規置換フェノール誘導体
JPH08325264A (ja) 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規２−芳香環置換−３−フェニルプロピオン酸またはアクリル酸誘導体
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
ATE259227T1 (de) * 1995-09-18 2004-02-15 Ligand Pharm Inc Behandlung von niddm (nichtinsulinabhängige diabetes mellitus) mit rxr agonisten
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
AU721452B2 (en) * 1996-02-02 2000-07-06 Merck & Co., Inc. Antidiabetic agents
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
FR2749583B1 (fr) * 1996-06-07 1998-08-21 Lipha Nouveaux derives de thiazolidine -2,4- dione substitues, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant
AU4050797A (en) * 1996-08-02 1998-02-25 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
CZ53699A3 (cs) 1996-08-19 1999-07-14 Japan Tobacco Inc. Deriváty propionové kyseliny a jejich použití
WO1998029120A1 (en) * 1996-12-31 1998-07-09 The Salk Institute For Biological Studies Treatment of liposarcomas using a combination of thiazolidinediones and retinoid x receptor selective agonists
US5814647A (en) * 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
WO1998043081A1 (en) * 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Treatment of gastrointestinal disease with ppar modulators
US6166192A (en) * 1997-05-30 2000-12-26 Dana-Farber Cancer Institute PGC-1, a novel brown fat PPARγ coactivator
US5925657A (en) * 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
AU8588798A (en) * 1997-07-25 1999-02-16 Institut Pasteur Human peroxisome proliferator activated receptor gamma (ppargamma) gene re gulatory sequences and uses therefor
BR9814087A (pt) * 1997-10-17 2000-10-03 Aventis Pharm Prod Inc Processos para mediar a atividade do receptor de ppar-gama, e para tratar uma condição fisiológica em um paciente
WO1999019313A1 (en) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999029317A1 (en) * 1997-12-12 1999-06-17 Purdue Research Foundation Methods and compositions for treating diabetes
EA200000687A1 (ru) * 1997-12-19 2000-12-25 Мерк Энд Ко., Инк. Производные арилтиазолидиндиона
WO1999038850A1 (en) * 1998-01-29 1999-08-05 Dr. Reddy's Research Foundation Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
KR100620337B1 (ko) * 1998-03-10 2006-09-13 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제
GB2335597A (en) 1998-03-27 1999-09-29 Glaxo Group Ltd Stereoisomers of Troglitazone in the Treatment of Diabetes
AU3333399A (en) * 1998-04-06 1999-10-25 Janssen Pharmaceutica N.V. Nucleotide sequence expressing human fatty acid transport protein and corresponding aminoacid sequence. use for the regulation of fatty acids metabolism
WO1999058510A1 (en) * 1998-05-11 1999-11-18 Takeda Chemical Industries, Ltd. Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
MA26662A1 (fr) * 1998-07-21 2004-12-20 Smithkline Beecham Plc Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation
EP1098639B1 (en) * 1998-07-21 2005-02-09 SmithKline Beecham plc Use of the glucose uptake enhancer rosiglitazone for reducing ischaemia-induced apoptosis of pancreatic beta cells, endothelial cells and neuronal cells
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
PT1206457E (pt) 2004-03-31
DE60005973D1 (de) 2003-11-20
PE20010529A1 (es) 2001-05-18
DE60005973T2 (de) 2004-05-13
US6825222B2 (en) 2004-11-30
JP2003508389A (ja) 2003-03-04
US6417212B1 (en) 2002-07-09
US6610696B2 (en) 2003-08-26
US20040019090A1 (en) 2004-01-29
ES2204684T3 (es) 2004-05-01
WO2001016120A9 (en) 2002-07-11
ATE252091T1 (de) 2003-11-15
US20030045558A1 (en) 2003-03-06
CA2382966A1 (en) 2001-03-08
EP1206457A1 (en) 2002-05-22
DK1206457T3 (da) 2004-02-16
WO2001016120A1 (en) 2001-03-08
AU7073400A (en) 2001-03-26
EP1206457B1 (en) 2003-10-15

Similar Documents

Publication Publication Date Title
AR025386A1 (es) Moduladores de los receptores activados del proliferador de peroxisomas
AR055053A1 (es) Compuestos indol sustituidos con actividad inhibidora de nos. composiciones farmaceuticas.
ES2080815T3 (es) Derivados de la 1-naftil-piperacina, sus procedimientos de preparacion y composiciones farmaceuticas que los contienen.
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
PE20090042A1 (es) Analogos de ciclopamina
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
CO5690588A2 (es) Derivados de 4-tetrazolilo-4 fenilpiperidina para el trata- miento del dolor
AR019153A1 (es) Compuestos de beta-carbolina, composicion farmaceutica que los contiene, su uso para la manufactura de un medicamento y compuesto intermediario
CO5611195A2 (es) Novedosos inhibidores de la gamma secretasa
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
AR053149A1 (es) Uso de compuestos de diosmetina para la obtencion de composiciones farmaceuticas destinadas a la prevencion y/o tratamiento de patologias tromboticas y patologias que conlleven el riesgo de producir trombosis
AR072798A1 (es) Derivados de pirido-piridinonas, su preparacion, composicion farmaceutica y su uso en el tratamiento de las enfermedades ligadas a la actividad de la proteina quinasa
GB1046506A (en) Guanidine compounds and process for their manufacture
ES2118203T3 (es) Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
AR041883A1 (es) Compuestos de piridopirimidinona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2105549T3 (es) Nuevos derivados fenoxi-isobutiricos sustituidos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
NO982921L (no) Nye kromenforbindelser, en fremgangsmÕte for deres fremstilling og farmas°ytiske sammensetninger som inneholder disse
AR112794A1 (es) Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso en el tratamiento de enfermedades inducidas por mutaciones idh
AR051325A1 (es) Analogos de biarilquinolin-4-ilamina sustituidos
AR027454A1 (es) Derivados de beta-alanina, utiles como antagonistas de receptores, las composiciones farmaceuticas que las contienen y el uso de los mismos para lapreparacion de medicamentos
AR072486A1 (es) Derivados de benzotiadiazinas cicloalquiladas su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CO5180536A1 (es) Inhibidores de proteasas catepsina
CO4950554A1 (es) Derivados de 1,3-dihidro o 3,4-dihidroisoquinolin-benzamida
ES2174582T3 (es) Nuevos derivados de 1,2-ditiolano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ATE184597T1 (de) Substituierte sulfonamide, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen